The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).
K. Phillips
No relevant relationships to disclose
R. L. Milne
No relevant relationships to disclose
M. A. Rookus
No relevant relationships to disclose
D. Goldgar
No relevant relationships to disclose
M. Friedlander
No relevant relationships to disclose
S. McLachlan
No relevant relationships to disclose
S. S. Buys
No relevant relationships to disclose
A. C. Antoniou
No relevant relationships to disclose
K. E. Birch
No relevant relationships to disclose
M. B. Terry
No relevant relationships to disclose
D. Easton
No relevant relationships to disclose
P. Weideman
No relevant relationships to disclose
M. B. Daly
No relevant relationships to disclose
N. Andrieu
No relevant relationships to disclose
E. M. John
No relevant relationships to disclose
M. Hooning
No relevant relationships to disclose
I. L. Andrulis
No relevant relationships to disclose
T. Caldes
No relevant relationships to disclose
H. Olsson
No relevant relationships to disclose
J. L. Hopper
No relevant relationships to disclose